Ocular Therapeutix Inc (OCUL)

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Sold by Ieq Capital LLC - Defense World

Defense World

Ocular Therapeutix: 2Q Earnings Snapshot - Yahoo News UK

Yahoo News UK

Ocular Therapeutix: 2Q Earnings Snapshot - Yahoo News UK

Yahoo News UK

When the Price of (OCUL) Talks, People Listen - Stock Traders Daily

Stock Traders Daily

Read This Before Selling Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares - Yahoo New Zealand News

Yahoo New Zealand News

Ocular Therapeutix (OCUL) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Canada Shine On

Yahoo Canada Shine On

Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Lifestyle UK

Yahoo Lifestyle UK

Loss-Making Ocular Therapeutix, Inc. (NASDAQ:OCUL) Expected To Breakeven - Yahoo New Zealand News

Yahoo New Zealand News

Ocular Therapeutix (NASDAQ:OCUL) Trading 7.8% Higher - MarketBeat

MarketBeat

Q2 2024 EPS Estimates for Ocular Therapeutix, Inc. Decreased by HC Wainwright (NASDAQ:OCUL) - MarketBeat

MarketBeat

Ocular Therapeutix (NASDAQ:OCUL) Trading Down 7% - Defense World

Defense World

Analysts Set Ocular Therapeutix, Inc. (NASDAQ:OCUL) Target Price at $15.17 - MarketBeat

MarketBeat

Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Lifestyle UK

Yahoo Lifestyle UK

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World

Defense World

Ocular Therapeutix (NASDAQ:OCUL) Trading Down 7% - MarketBeat

MarketBeat

Ocular Therapeutix (NASDAQ:OCUL) shareholders have endured a 21% loss from investing in the stock five years ago - Yahoo Movies UK

Yahoo Movies UK

Ocular Therapeutix (NASDAQ:OCUL) Price Target Cut to $22.00 by Analysts at JMP Securities - Defense World

Defense World

HC Wainwright Lowers Ocular Therapeutix (NASDAQ:OCUL) Price Target to $14.00 - Defense World

Defense World

Ocular Therapeutix (NASDAQ:OCUL) Trading Down 7% - MarketBeat

MarketBeat

Implied Volatility Surging for Ocular Therapeutix (OCUL) Stock Options - Yahoo News UK

Yahoo News UK

Ocular Therapeutix (NASDAQ:OCUL) Price Target Cut to $14.00 - MarketBeat

MarketBeat

Ocular Therapeutix (NASDAQ:OCUL) Price Target Cut to $14.00 - MarketBeat

MarketBeat

Ocular Therapeutix: Q1 Earnings Snapshot - Houston Chronicle

Houston Chronicle

Ocular Therapeutix Inc Reports First Quarter 2024 Earnings - Yahoo Finance

Yahoo Finance

Ocular Therapeutix Inc earnings missed by $0.31, revenue fell short of estimates - Investing.com India

Investing.com India

Ocular Therapeutix: Q1 Earnings Snapshot - Houston Chronicle

Houston Chronicle

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

GlobeNewswire

Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences - Investing.com India

Investing.com India

Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences - GlobeNewswire

GlobeNewswire

Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences - Yahoo Finance

Yahoo Finance

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

GlobeNewswire

Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024 - GlobeNewswire

GlobeNewswire

Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024

GlobeNewswire Inc.

Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024 - GlobeNewswire

GlobeNewswire

Ocular Therapeutix (NASDAQ:OCUL) Trading 10% Higher - MarketBeat

MarketBeat

Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024

GlobeNewswire Inc.

Wall Street Breakfast: The Week Ahead

Seeking Alpha

2 Small-Cap Growth Stocks With Room to Run

The Motley Fool

Baird sees weakness in Ocular shares as "overdone" (NASDAQ:OCUL) - Seeking Alpha

Seeking Alpha

Ocular reports promising results for diabetic retinopathy treatment - Investing.com Nigeria

Investing.com Nigeria

Ocular Therapeutix (NASDAQ:OCUL) Shares Gap Up to $7.79 - MarketBeat

MarketBeat

The Analyst Verdict: Ocular Therapeutix In The Eyes Of 8 Experts

Benzinga

The Analyst Verdict: Ocular Therapeutix In The Eyes Of 8 Experts - Ocular Therapeutix (NASDAQ:OCUL) - Benzinga

Benzinga

Ocular Therapeutix appoints new CEO amid leadership shift - Investing.com

Investing.com

Sustained Release Ocular Drug Delivery Systems Market Analysis to 2030 | Allergan, Icon Bioscience, Ocular ... - Currency News Centre

Currency News Centre

Down -17.88% in 4 Weeks, Here's Why Ocular Therapeutix (OCUL) Looks Ripe for a Turnaround

Zacks Investment Research

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics

GlobeNewswire Inc.

Down -17.88% in 4 Weeks, Here's Why Ocular Therapeutix (OCUL) Looks Ripe for a Turnaround - Yahoo Finance

Yahoo Finance

Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting

GlobeNewswire Inc.

Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract ... - GlobeNewswire

GlobeNewswire